Tripos Extends Its COMT Inhibitor Program with CeNeS Pharmaceuticals
Date Posted: Monday, September 18, 2006
Tripos, Inc. and CeNeS Pharmaceuticals plc have announced that they have extended their research agreement to develop catechol-O-methyltransferase (COMT) inhibitors to treat Parkinson's disease.
Tripos and CeNeS began this multiyear collaboration in 2003. Using Tripos' knowledge-driven chemistry process to investigate the inhibition of COMT with analogues of CeNeS' proposed leads, they succeeded in identifying several series of novel active compounds, thereby achieving a chemical breakaway from currently marketed COMT inhibitors.
Tripos and CeNeS are now jointly developing these lead series with a view to further optimizing in vitro and in vivo activity as well as their ADMET profile, thus addressing the known limitations associated with existing marketed therapies.
"Following on our previous successes, we are well positioned to continue progression through lead optimization and to deliver proof-of-concept data for one or more of our novel COMT inhibitors," said Dr. Gary Tilbrook, chemistry director for CeNeS.
"Our COMT discovery program has continued to perform to plan, and we are excited about its potential to deliver improved therapies for the treatment of Parkinson's disease."
"We are very pleased with the progress on this project," said Dr. Mark Allen, senior vice president and managing director of Tripos Discovery Research, Ltd., based in Bude, England.
"This partnership builds on each company's strengths, and we believe that it will continue to produce promising results."
Further Information: http://www.tripos.com
A Mild Protocol for Parallel Solution Phase Synthesis of Cyclic Imides
The combination of using high temperatures and coupling reagents allows production of cyclic imides rapidly and in higher purity than heat or coupling agents alone.
Tripos Announces Benchware Discovery 360
Scientists now able to access and analyze enterprise chemical and biological data from a single integrated desktop discovery environment.
Tripos Announces Benchware Discovery 360º
Benchware Discovery 360º is based on the SMART-IDEA™ informatics system.
Tripos Introduces Surflex-Dock Virtual Screening Software
Surflex-Dock is now fully integrated into Tripos’ SYBYL® molecular modeling environment.